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Mannose-Binding Lectin is a Disease-Modifying Factor
in North American Patients with Systemic Lupus
Erythematosus
WENHUA PIAO, CHAU-CHING LIU, AMY H. KAO, SUSAN MANZI, MOLLY T. VOGT, MARGIE J. RUFFING,
and JOSEPH M. AHEARN
ABSTRACT. Objective. To investigate whether development of systemic lupus erythematosus (SLE), its clinical man-
ifestations, and autoantibody production are associated with polymorphisms of the mannose-binding
lectin (MBL) gene in North American patients with SLE.
Methods. MBL gene polymorphisms in codons 52 (designated variant D, with the wild-type designat-
ed A), 54 (variant B), and 57 (variant C) were determined by polymerase chain reaction-sequence spe-
cific priming in 130 patients with SLE and 142 healthy controls. Autoantibodies against double-strand-
ed DNA (dsDNA), Smith antigen, phospholipids, Ro/SSA, La/SSB, and RNP were tested at certified
clinical pathology laboratories.
Results.A statistically significant increased likelihood of anti-Smith antibody production was observed
in SLE patients with the heterozygous A/B genotype [odds ratio (OR) 5.1; 95% confidence interval (CI)
1.6–16.6; the A/A genotype as the reference group] or A/C genotype (OR 8.2; 95% CI 2.0–33.9). SLE
patients with the homozygous or compound heterozygous variant genotype (O/O; O, a common desig-
nation for variant alleles) had an increased likelihood of mounting autoantibody responses against
dsDNA, Ro/SSA, and La/SSB, and were more likely to have a history of renal disease (OR 4.8; 95% CI
0.9–25.2). However, differences in the frequencies of MBL variant alleles and genotypes observed
between patients with SLE and controls did not reach statistical significance.
Conclusion. A significantly increased prevalence of anti-Smith antibody was associated with the het-
erozygous genotypes A/B and A/C. Although MBL structural gene polymorphism was not a risk factor
for SLE development in this study population, homozygosity of MBL variant alleles may be a weak dis-
ease-modifying factor, particularly for renal involvement, in North American patients with SLE.
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Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease characterized by autoantibody production and immune
complexes/complement-mediated inflammatory tissue dam-
age. While the etiopathogenesis of SLE remains elusive, a
combination of genetic and environmental factors is believed
to provoke development of the disease. There is compelling
evidence that complete deficiency of any of the early comple-
ment components (C1q, C2, and C4) is the strongest genetic
risk factor for SLE development1-3, with a hierarchical asso-
ciation with disease prevalence and severity. It has been
reported that 90%, 75%, and 30% of individuals deficient in
C1q, C4, and C2, respectively, develop SLE1-3. However,
homozygous complement deficiencies are extremely rare,
occurring in about 1% of patients4, suggesting the involve-
ment of other genetic factors in the majority of patients with
SLE.
Recently, the mannose-binding lectin (MBL) gene has
emerged as a candidate lupus gene due to the role of MBL in
innate immunity and the possible association between MBL
deficiency and disease (e.g., infections and autoimmune dis-
orders)5,6. MBL, which is structurally and functionally analo-
gous to C1q, is encoded by a single 4-exon gene located on
chromosome 10. MBL is a multi-chain molecule of up to 6
subunits. Each subunit consists of 3 identical 32-kDa polypep-
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tide chains that contain a cysteine–rich region, a collagenous
region, a “neck” region, and a carbohydrate-binding domain
encoded by exon 1, exon 2, exon 3, and exon 4, respective-
ly7,8. Mutations in the coding and promoter regions dramati-
cally affect serum levels of MBL8-10. Three point mutations at
nucleotides 223 (C to T), 230 (G to A), and 239 (G to A) of
exon 1, resulting in changes of amino acid residues 52 (Arg to
Cys), 54 (Gly to Asp), and 57 (Gly to Glu), give rise to 3 vari-
ant alleles D, B, and C, respectively11-13. Of the 3 structural
variant alleles, the B and C alleles lead to profound reduction
of serum MBL levels, whereas the D allele has minimal
impact. Two other variants commonly found in the promoter
region, H/L (due to nucleotide substitutions at position –550)
and Y/X (nucleotide substitution at position –221), also influ-
ence serum MBL levels14. In particular, the X allele (a G to C
substitution) is associated with low serum MBL concentra-
tions10.
As part of the complement system, MBL is responsible for
initiating the lectin pathway. In light of its structural and func-
tional similarities to C1q and the strong association of C1q
deficiency with SLE, MBL variant alleles that lead to low
serum levels and/or functional deficits of MBL are postulated
to contribute to the susceptibility of SLE. However, reports of
the effects of MBL polymorphisms on SLE development vary
considerably. MBL deficiency due to variant alleles has been
identified as a risk factor for developing SLE in African
American, Chinese, and Japanese populations15-18, and the
risk was greater if combined with defects in Fcγ receptors19 or
C4B null alleles20. In several studies using patients of differ-
ent ethnic origins, MBL variant alleles have been identified
either as a minor risk factor21,22 or not a risk factor23 for
developing SLE. The influence of MBL gene variants on
autoantibody production24,25 and organ involvement15,22 in
patients with SLE also remains controversial. Such diverse
results may originate from differences in sample size, homo-
geneity of samples, selection of controls, or ethnic back-
ground of patient populations in different studies26.
In view of the inconsistent reports concerning the role of
MBL gene polymorphism in SLE and the lack of rigorous
studies of MBL variants in patients with SLE in the United
States, we investigated the association of MBL polymorphisms
with SLE and its clinical manifestations and autoantibody pro-
duction in a large cohort of well characterized patients with
SLE and healthy controls (predominantly Caucasian women)
followed at a major medical center in the US.
MATERIALS AND METHODS
Patients with SLE and controls. Patients with SLE were recruited for this
study during routine visits to the University of Pittsburgh Lupus Translational
Research and Patient Care Center. All patients met the 198227 or 199728
American College of Rheumatology revised criteria for the classification of
definite SLE. As part of their routine care, all patients underwent a history-
taking and examination by one physician. Blood was drawn at their routine
visits. Disease activity was assessed at the time of the visit using the Systemic
Lupus Activity Measure (SLAM)29 and the Safety of Estrogens in Lupus
Erythematosus: National Assessment (SELENA) version of the SLE Disease
Activity Index (SLEDAI)30. Controls were recruited through advertisements
posted on the University of Pittsburgh campus. A total of 130 patients with
SLE and 142 controls were enrolled. To confirm their health status, all par-
ticipants completed a brief questionnaire regarding existing medical condi-
tions. Ethnicity was self-reported by the subjects. Informed consent was
obtained from the patients and controls. The University of Pittsburgh
Institutional Review Board approved our study.
Detection of MBL structural variant alleles. Genomic DNA was extracted
from peripheral blood cells using reagents provided in the REDExtract-N-
Amp Blood PCR Kit (Sigma, St. Louis, MO, USA) following the manufac-
turer’s instruction. MBL variant alleles were detected using the polymerase
chain reaction-sequence specific priming (PCR-SSP) technique31 (see Table
1 for primer sequences). The B and C alleles were detected by PCR with con-
fronting primers using modified conditions of Hamajima, et al32. The AnonD
and D alleles were detected in separate PCR because of the difficulty of con-
fronting primer design. Oligonucleotide primers encoding sequences within
exon 4 of the MBL gene were used to amplify an internal control fragment.
PCR were performed in a volume of 20 µl containing 1.5 mM of MgCl2, 50
µM of dNTP, 0.025 U/µl of Platinum Taq DNA polymerase (Invitrogen,
Carlsbad, CA, USA), 0.28 µM of internal control primers, 1.0 µM of
AnonB/AnonC forward primers and B/C reverse primers, 0.8 µM of
AnonB/AnonC reverse primers and B/C forward primers, and 0.4 µM of
AnonD and D primers. All PCR were initiated by 3 min of denaturation at
94°C and completed by 10 min of extension at 72°C. PCR cycles were as fol-
lows: 30 cycles of 30 s at 94°C, 30 s at 56°C, and 45 s at 72°C. PCR ampli-
cons were resolved on 2% agarose gels containing ethidium bromide and
visualized by UV transillumination.
Statistical analysis. The allelic and genotypic frequencies of the MBL genes
for patients with SLE and controls were compared, and Fisher’s exact test was
used to assess the statistical significance of differences (GraphPad,
QuickCalcs, online calculator). The significance of the associations between
MBL genotypes and autoantibody production or clinical features in patients
with SLE was also tested using Fisher’s exact test. Four dummy variables
were constructed for genotypes A/B, A/C, A/D, and O/O (wild-type A/A was
the referent group), and the association between the MBL genotypes and
autoantibody production or clinical phenotypes was estimated by odds ratios
(OR) with 95% confidence interval (CI) using logistic regression analysis by
SPSS statistical software (Version 11.0 for Windows). All tests were 2-tailed.
P values < 0.05 were considered statistically significant.
RESULTS
Amultiethnic cohort of 130 patients with SLE (female/male =
128/2; Caucasian/African American/other races = 109/18/3;
mean age = 44.35 ± 12.25 yrs) and 142 controls (F/M =
132/10; Caucasian/African American/other races = 130/7/5;
mean age = 43.91 ± 11.55 yrs) were examined for single
nucleotide polymorphisms at codon 52(D), codon 54(B), and
codon 57(C) of exon 1 of the mbl2 gene by PCR using
sequence-specific primers. As summarized in Table 2, allele
frequencies and genotype distribution were comparable in
patients with SLE and controls. The distribution of MBL
genotypes in both controls and patients with SLE showed
good probability of fitness with Hardy-Weinberg equilibrium
(data not shown).
When the SLE patient cohort and control group were strat-
ified by ethnicity, comparable allele and genotype distribu-
tions in patients with SLE versus controls were observed in
both Caucasian and African American groups, with an excep-
tion for the D allele (Table 2C). The frequencies of the D
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allele and A/D genotype were higher in healthy African
Americans (14.3% and 28.6%, respectively) than in African
American patients with SLE (0% and 0%, respectively). The
MBL allele frequencies and genotype distribution in study
participants of other races were not separately analyzed due to
their small numbers (3 patients with SLE, all A/A genotype; 5
healthy individuals, 3 A/A genotype and 2 A/B genotype).
Overall, there appeared to be an increase in the prevalence
of the A/C genotype among this multiethnic cohort of patients
with SLE (12/130 = 9.2% vs 5/142 = 3.5%; Table 2A), partic-
ularly in the African American patients (7/18 = 38.9% vs 1/7
= 14.3%; Table 2C). Such subtle, although statistically
insignificant, increases in the prevalence of heterozygous
MBL genotypes in patients with SLE prompted us to explore
further the potential effects of the MBL variant alleles/defi-
ciency genotypes on serological and clinical manifestations of
SLE.
To examine the relationship between MBL gene polymor-
phisms and autoantibody production, the prevalence of sever-
al autoantibodies in SLE patients with different MBL geno-
types was analyzed. The results showed that SLE patients
with the O/O genotype were more likely to produce anti-
dsDNA (100% in O/O vs 65.3% in A/A and 63.8% in A/O)
and other autoantibodies (anti-Ro/SSA, anti-La/SSB, and
anti-RNP — 50.0% in O/O vs 34.7% in A/A and 36.2% in
A/O), but less likely to produce antiphospholipid antibodies
(anticardiolipin and/or lupus anticoagulant — 25.0% in O/O
vs 50.7% in A/A and 44.7% in A/O) and anti-Smith antibody
(0% in O/O vs 8.0% in A/A and 29.8% in A/O; p < 0.001;
Table 3A). In comparison, patients with the A/O genotype
were mostly likely to develop anti-Smith antibodies. The sta-
tistically significant increase in the prevalence of anti-Smith
antibody in SLE patients with the A/O genotype was further
investigated. The data revealed that patients with the A/B and
A/C genotype were more likely to develop anti-Smith anti-
body (30.8% and 41.7%, respectively) than those with the
A/D genotype (12.5%) and the O/O genotype (0.0%; Table
3B). Logistic regression analysis further showed that SLE
patients with the heterozygous variant genotype A/B or A/C,
as compared to those with the A/A genotype, were several
times more likely to have anti-Smith antibodies (OR 5.1; 95%
CI 1.6–16.6 for A/B and OR 8.2; 95% CI 2.0–33.9 for A/C;
Table 4).
The correlation of clinical features, including renal disease,
cardiovascular disease, neurologic disease, hematologic dis-
ease, malar rash, discoid rash, photosensitivity, oral ulcers,
and serositis, with MBL polymorphisms was also evaluated.
The prevalence of different clinical features varied across SLE
patients with different MBL genotypes. The only variable that
reached statistical significance was renal disease (p = 0.035;
Table 5). Logistic regression modeling indicated that patients
with the O/O genotype were almost 5 times more likely to
have renal involvement (OR 4.8; 95% CI 0.9–25.2) than
patients with the A/A genotype (Table 6).
DISCUSSION
We examined MBL structural polymorphisms at codon 52
(allele D), codon 54 (allele B), and codon 57 (allele C) in a
multiethnic cohort of 130 patients with SLE (84% Caucasians,
14% African Americans, and 2% other races) who were
recruited at a major US medical center. Although differences
in allelic and genotypic frequencies observed between
patients with SLE and controls did not reach statistical signif-
icance, the D allele and A/D genotype appeared to occur less
frequently in African American patients with SLE than in
healthy African Americans (Table 2C). Because of the size of
the African American cohort (18 patients with SLE and 7 con-
trols), it is premature to conclude that the D allele and A/D
genotype are protective against the development of SLE in
AfricanAmerican patients. Notably, the prevalence of theA/C
genotype was higher in patients with SLE (especially African
American patients) than healthy controls (Tables 2A and 2C).
Production of anti-Smith antibody, which is specific for lupus,
was most prevalent among SLE patients with the A/C geno-
Table 1. Sequences of PCR-SSP primers for the mbl2 gene.
Allele Sequence Product Size
AnonB Forward 5’AGT CGA CCC AGA TTG TAG GAC AGA G 3” 277 bp
Reverse 5’ CCT TTT CTC CCT TGG TGC 3’
B Forward 5’ GCAAAG ATG GGC GTG ATG A 3’ 224 bp
Reverse 5’ GGG CTG GCAAGA CAA CTA TTA 3’
AnonC Forward 5’ACT CGA CCC AGA TTG TAG GAC AGA G 3’ 287 bp
Reverse 5’ CCT GGT TCC CCC TTT TCT C 3’
C Forward 5’ CAAAGA TGG GCG TGA TGG CAC CAA GGA 3’ 222 bp
Reverse 5’ GGG CTG GCAAGA CAA CTA TTA 3’
AnonD Forward 5’AGT CGA CCC AGA TTG TAG GAC AGA G 3’ 270 bp
Reverse 5’ TCC CTT GGT GCC ATC ACG 3’
D Forward 5’AGT CGA CCC AGA TTG TAG GAC AGA G 3’ 271 bp
Reverse 5’ CTC CCT TGG TGC CAT CAC A 3’
Exon 4 Forward 5’ GAG TTT CAC CCA CTT TTT CAC A 3’ 421 BP
Reverse 5’ GCC TGA GTG ATA TGA CCC TTC 3’
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type (Tables 3B and 4). Moreover, SLE patients with the O/O
genotype were prone to have anti-dsDNA autoantibodies and
renal involvement (Tables 3 and 5). Together, these results
suggest that heterozygosity or homozygosity of MBL variant
allele may be a minor risk factor and/or a disease modifying
factor for SLE in this cohort of patients with SLE.
MBL variant alleles are found frequently in the general
population9,10. Single nucleotide substitutions occurring in
both the promoter and structure-coding regions of the mbl2
gene may result in decreased synthesis of MBL or production
of dysfunctional MBL variants incapable of oligomerization,
thereby causing quantitative and qualitative deficiencies in
MBL10,33-35. MBL deficiency has been implicated in suscep-
tibility to infections and autoimmune diseases5,11,22,36-38.
MBL has been shown to bind directly to apoptotic cells and
necrotic cells and initiate their removal by macrophages39,40.
It can therefore be postulated that insufficient levels of MBL
may predispose patients to the accumulation of apoptotic
cells. These cells may serve as a major source of autoantigens,
and hence induce autoantibody production in patients with
SLE41-43. Autoantibodies generated against such autoantigens
target primarily nuclear components such as dsDNA, nuclear
ribonucleoprotein (nRNP), Ro/SSA, La/SSB, and Smith anti-
gen. Among these autoantibodies, anti-Smith antibody, which
is against the core polypeptides of the spliceosome complex,
is highly specific for SLE and is present in 15%–30% of
patients with SLE. In our study, heterozygous A/B and A/C
genotypes of MBL were found to be associated with an
increased probability of generation of anti-Smith antibody
(OR 5.1, p = 0.007 for A/B genotype; OR 8.2, p = 0.004 for
A/C genotype). Interestingly, however, SLE patients with the
O/O genotype were less likely to produce anti-Smith antibody,
but more likely to produce anti-dsDNA and Ro/SSA, La/SSB,
and RNP antibodies (Tables 3 and 4). These results, together,
not only support the hypothetical link between MBL deficien-
cy, apoptosis, and SLE, but also imply the complex interplay
between genetic factors and autoantibody phenotypes in dif-
ferent individuals. In this context, it is postulated that the
extent of MBL deficiency (more profound in patients with the
O/O genotype than in those with the A/O genotypes) may
influence differentially the clearance of different subsets of
apoptotic debris and hence the generation of different autoan-
tibodies in individual patients with SLE.
Quantitative or functional deficiency of MBL may also
lead to insufficient activation of the complement system and
inadequate clearance of immune complexes, which in turn
result in immune complex deposition in tissues and cause
organ damage. The factors that influence the involvement of
different target organs in individual patients with SLE are cur-
rently unknown. More than 90% of people with C1q deficien-
cy develop SLE, but only one-third of them develop glomeru-
lonephritis1. The existence has been suggested of nephropathy
susceptibility genes independent of SLE susceptibility
genes44. Garred, et al have reported that renal involvement
Table 2.Allelic and genotypic frequencies of MBL variants in patients with
SLE and healthy controls.
2A. Analysis of the entire multiethnic cohort.
SLE, n = 130 Healthy Control, n = 142 p*
(%) (%)
Allele
A 197 (75.8) 218 (76.8) 0.840
B 33 (12.7) 33 (11.6) 0.793
C 16 (6.1) 11 (3.9) 0.241
D 14 (5.4) 22 (7.7) 0.303
Genotype
A/A 75 (57.7) 87 (61.3) 0.621
A/B 26 (20.0) 26 (18.3) 0.759
A/C 12 (9.2) 5 (3.5) 0.077
A/D 9 (6.9) 13 (9.2) 0.657
O/O† 8 (6.2) 11 (7.7) 0.642
A/O 47 (36.1) 44 (31.0) 0.372
* SLE vs controls, Fisher’s exact test. † O/O distribution in SLE: B/B (1),
B/C (2), B/D (3), C/C (1), D/D (1). O/O distribution in controls: B/C (2),
B/D (5), C/C (1), C/D (2), D/D (1).
2B. Analysis of the Caucasian cohort.
SLE, n = 109 Healthy Control, n = 130 p*
(%) (%)
Allele
A 168 (77.1) 199 (76.5) 0.914
B 31 (14.2) 31 (11.9) 0.496
C 5 (2.3) 10 (3.8) 0.433
D 14 (6.4) 20 (7.7) 0.721
Genotype
A/A 64 (58.7) 80 (61.5) 0.692
A/B 26 (23.9) 24 (18.5) 0.340
A/C 5 (4.6) 4 (3.1) 0.736
A/D 9 (8.2) 11 (8.5) 1.000
O/O† 5 (4.6) 11 (8.5) 0.302
A/O 42 (36.7) 39 (30.0) 0.334
* SLE vs controls, Fisher’s exact test. † O/O distribution in SLE: B/B (1),
B/D (3), D/D (1). O/O distribution in controls: B/C (2), B/D (5), C/C (1),
C/D (2), D/D (1).
2C. Analysis of the African American cohort.
SLE, n = 18 Healthy Control, n = 7 p*
(%) (%)
Allele
A 23 (63.9) 11 (78.6) 0.501
B 2 (5.5) 0 (0.0) 1.000
C 11 (30.6) 1 (7.1) 0.140
D 0 (0.0) 2 (14.3) 0.074
Genotype
A/A 8 (44.4) 4 (57.1) 0.673
A/B 0 (0.0) 0 (0.0) 1.000
A/C 7 (38.9) 1 (14.3) 0.362
A/D 0 (0.0) 2 (28.6) 0.070
O/O† 3 (16.7) 0 (0.0) 0.534
A/O 7 (38.9) 3 (42.8) 1.000
* SLE vs controls, Fisher’s exact test. † O/O distribution in SLE: B/C (2),
C/C (1). O/O distribution in controls: 0.
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was more frequent in European Caucasian (Danish) SLE
patients with the O/O genotypes22. Similarly, among patients
with SLE in our multiethnic, yet Caucasian-dominant, cohort
(84%American Caucasians, 14%African Americans, and 2%
other races), those with the O/O genotype were more likely to
report renal events (Tables 5 and 6). However, in a recent
study conducted with a multiethnic cohort dominant in non-
Caucasian patients (31% American Caucasians, 40% African
Americans, and 29% Hispanics), it was reported that renal
involvement was more likely to occur in patients with the
wild-type allele (A/A) than patients with MBL variant alleles
(A/O and O/O)45. Collectively, these seemingly inconsistent
data suggest that MBL deficiency may be a weak risk factor
for renal disorders in SLE patients of certain ethnicities.
Nevertheless, it should be cautioned that the numbers of
patients with the O/O genotype were small in the study by
Garred, et al (n = 7; total patients studied = 91) and our study
(n = 8; total patients studied = 130), which may pose consid-
erable limitations in statistical analyses. Therefore, further
Table 3. Presence of autoantibodies in patients with SLE stratified by MBL genotypes.
3A.
Genotype
A/A, n = 75 A/O, n = 47 O/O, n = 8
Autoantibodies (%) (%) (%) p*
Anti-dsDNA 49 (65.3) 30 (63.8) 8 (100.0) 0.120
Anti-Smith** 6 (8.0) 14 (29.8) 0 (0.0) < 0.001
Antiphospholipid† 38 (50.7) 21 (44.7) 2 (25.0) 0.357
Other antibodies†† 26 (34.7) 17 (36.2) 4 (50.0) 0.692
3B.
Genotype
A/A, n = 75 A/B, n = 26 A/C, n = 12 A/D, n = 9 O/O, n = 8
Autoantibodies (%) (%) (%) (%) (%) p*
Anti-dsDNA 49 (65.3) 17 (65.4) 8 (66.7) 5 (55.6) 8 (100.0) 0.332
Anti-Smith** 6 (8.0) 8 (30.8) 5 (41.7) 1 (12.5) 0 (0.0) 0.003
Antiphospholipid† 38 (50.7) 11 (42.3) 7 (58.3) 3 (33.3) 2 (25.0) 0.480
Other antibodies†† 26 (34.7) 8 (30.8) 6 (50.0) 3 (33.3) 4 (50.0) 0.719
* Fisher’s test. ** 129 SLE patients were tested for anti-Smith antibody. † Antiphospholipid includes anticardio-
lipin and lupus anticoagulant. †† Other autoantibodies include any one or combinations of SSA/Ro, SSB/La, or
RNP antibody.
Table 4. Logistic regression analysis of prevalence of anti-Smith antibody
in patients with SLE.
Genotypes p* Odds Ratio 95% CI
A/B 0.007 5.1 1.6–16.6
A/C 0.004 8.2 2.0–33.9
A/D 0.666 1.6 0.2–15.7
O/O 0.999 0.0 0.0–infinity
* Heterozygous and homozygous variant genotypes vs wild-type genotype
A/A.
Table 5. Clinical features of SLE patients with different MBL genotypes.
Genotype
A/A, n = 75 A/B, n = 26 A/C, n = 12 A/D, n = 9 O/O, n = 8
Features (%) (%) (%) (%) (%) p*
Malar rash 37 (49.3) 11 (42.3) 6 (50.0) 4 (44.4) 6 (75.0) 0.608
Discoid rash 10 (13.3) 2 (7.7) 4 (33.3) 1 (11.1) 3 (37.5) 0.111
Photosensitivity 38 (50.7) 15 (57.7) 4 (33.3) 5 (55.6) 6 (75.0) 0.433
Oral ulcers 44 (58.7) 10 (38.5) 7 (58.3) 5 (55.6) 4 (50.0) 0.504
Serositis† 54 (73.0) 22 (84.6) 10 (83.3) 7 (77.8) 8 (100.0) 0.326
Renal event 29 (38.7) 14 (53.8) 3 (27.3) 1 (11.1) 6 (75.0) 0.035
Cardiovascular event 14 (18.7) 6 (23.1) 5 (41.7) 1 (11.1) 3 (37.5) 0.298
Neurologic event 13 (17.3) 3 (11.5) 2 (16.7) 1 (11.1) 2 (25.0) 0.891
Hematologic event 42 (56.0) 15 (57.7) 8 (66.7) 7 (77.8) 8 (100.0) 0.122
* Fisher’s test. † 129 SLE patients were tested for serositis.
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studies using larger patient populations are needed before
definitive conclusions can be reached about the association of
MBL polymorphisms with specific clinical features in ethnic
patients with SLE.
Recently, a prospective study using 91 Danish patients
with SLE has shown that vascular, particularly arterial throm-
botic, events occurred more frequently in patients with the
O/O genotype, suggesting that MBL deficiency is a risk factor
for thrombotic cardiovascular disease in SLE46. However, dis-
agreeing results have been reported in 2 other studies using
either a German cohort47 or a multiethnic (American
Caucasian/African American/Hispanic) cohort of patients
with SLE48. In this regard, the small number of vascular
events accrued in our patient cohort prohibited the perform-
ance of meaningful statistical analyses. Further investigation
of the role of MBL polymorphisms in thrombotic vascular
events in SLE is warranted.
The association of MBL polymorphism/deficiency with
SLE in various ethnic groups has been extensively investigat-
ed. An early study conducted in African American patients
with SLE showed a significant increase in the frequencies of
B and C alleles15. Significant increases in the frequency of the
B allele in Spanish patients with SLE20 and B/B genotype in
Japanese patients with SLE17,18 have also been reported.
These results suggest that MBL deficiency, due in particular to
the B variant allele, is associated with development of SLE. In
contrast, Horiuchi, et al reported no significant increase in the
frequency of the B allele in Japanese patients with SLE, con-
cluding that MBL polymorphism is not a risk factor for
SLE23.
In other studies with various ethnic groups, modest
increases in the frequency of MBL structural variant alleles in
patients with SLE compared to healthy controls have been
reported. For instance, increased frequencies of B and C alle-
les were found in South African patients49, increased B allele
frequency in Chinese50, British Caucasian21 and Greek
Caucasian patients51, and increased frequency of the O/O
genotype in Danish Caucasian patients22. Most of the
observed increases in MBL variant alleles in patients with
SLE, however, have not proved to be statistically significant
and, in some cases, were inconsistent among different studies.
In an attempt to reconcile the inconsistent observations, Lee
and colleagues recently conducted a metaanalysis of 15 pub-
lished studies of associations between MBL gene polymor-
phism and SLE26. Overall, these authors found a significantly
increased OR for association of the B allele with SLE (OR
1.41; 95% CI 1.22–1.61; p < 0.001) in African, Asian, and
Caucasian patients. Taken together, these studies suggest that
structural mutations of MBL have a significant, albeit minor,
influence on the susceptibility to SLE.
If deficiency of C1q, a complement component structural-
ly and functionally similar to MBL, is strongly associated
with susceptibility to SLE, why does MBL deficiency have no
significant association with SLE? C1q has been shown to play
important roles in complement activation, T cell-dependent
antibody production, and clearance of apoptotic cells52,53.
Such activities may be severely compromised in the absence
of C1q, leading to autoimmune reactivity and development of
SLE. In comparison, MBL may play a lesser, redundant role
in immune regulation. Thus, the presence of C1q may mask
the effect of MBL deficiency. The extreme rarity of homozy-
gous C1q deficiency (~20–30 cases worldwide) also under-
scores the detrimental effects of C1q deficiency in life and in
disease development in general, in contrast to the relatively
benign outcome of MBL deficiency. Deficiency/mutation of a
single gene product such as MBL may not correlate with SLE
because of genetic heterogeneity and epistatic interactions
among different genes in different ethnic populations, unless
the penetrance of a particular gene is high. These genetic vari-
ations may explain why the reported associations of MBL
gene polymorphism with SLE in different ethnic groups are
conflicting. MBL gene polymorphism may be important in
defining specific clinical features favored by concomitant
inherited or acquired risk factors.
Based on analyses of organ involvement and antibody pro-
duction profiles, our study showed that MBL variant alle-
les/deficiency genotypes may be a weak risk factor for clini-
cal subsets of patients with SLE. However, as in other ethnic
groups previously reported, MBL variant alleles/deficiency
genotypes per se do not seem to play a major role in the devel-
opment of SLE in North American patients. It should be cau-
tioned, however, that this study population consists predomi-
nantly of American Caucasians; thus, whether similar associ-
ations of MBL deficiency genotypes with renal involvement
exist in African American patients with SLE warrants further
investigation. Interestingly, a recent study evaluating a multi-
ethnic (Hispanic, African American, and Caucasian) cohort of
patients with SLE showed that MBL deficiency genotypes
were associated with cerebrovascular events in Caucasian
patients but not in Hispanic and African American patients48,
reinforcing the possibility that the relationship between MBL
variant alleles/deficiency genotypes and renal disease may
exist only in SLE patients of certain ethnic groups.
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Table 6. Odds ratio and 95% CI from the binary logistic regression analy-
sis of renal events in 130 patients with SLE.
Genotypes p* Odds Ratio 95% CI
A/B 0.180 1.9 0.8–4.6
A/C 0.469 0.6 0.1–2.4
A/D 0.137 0.2 0.0–1.7
O/O 0.067 4.8 0.9–25.2
* Heterozygous and homozygous variant genotypes vs wild-type genotype
A/A.
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